Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP-E2F1-DNA damage response pathway axis.

Oku, Yusuke; Nishiya, Naoyuki; Tazawa, Takaaki; Kobayashi, Takaya; Umezawa, Nanami; Sugawara, Yasuyo; Uehara, Yoshimasa

Oku, Yusuke; Nishiya, Naoyuki; Tazawa, Takaaki; Kobayashi, Takaya; Umezawa, Nanami; Sugawara, Yasuyo; Uehara, Yoshimasa.

Affiliation

Oku Y; Department of Integrated Information for Pharmaceutical Sciences Iwate Medical University School of Pharmacy Yahaba-cho Japan.
Nishiya N; Department of Integrated Information for Pharmaceutical Sciences Iwate Medical University School of Pharmacy Yahaba-cho Japan.
Tazawa T; Department of Integrated Information for Pharmaceutical Sciences Iwate Medical University School of Pharmacy Yahaba-cho Japan.
Kobayashi T; Department of Integrated Information for Pharmaceutical Sciences Iwate Medical University School of Pharmacy Yahaba-cho Japan.
Umezawa N; Department of Integrated Information for Pharmaceutical Sciences Iwate Medical University School of Pharmacy Yahaba-cho Japan.
Sugawara Y; Department of Integrated Information for Pharmaceutical Sciences Iwate Medical University School of Pharmacy Yahaba-cho Japan.
Uehara Y; Department of Integrated Information for Pharmaceutical Sciences Iwate Medical University School of Pharmacy Yahaba-cho Japan.

FEBS Open Bio ; 8(6): 1001-1012, 2018 Jun.

Article de En | MEDLINE | ID: mdl-29928579

Mots clés

AZD1775; DNA damage; YAP; combination therapy; dasatinib

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: FEBS Open Bio Année: 2018 Type de document: Article Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google